Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using ...

Kymera Therapeutics KYMR will release its quarterly earnings report on Friday, 2025-05-09. Here's a brief overview for investors ahead of the announcement.

WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using ...

Kymera Therapeutics' shares have dropped from $81 to $39 since my note back in 2021, but have risen >130% in the past 6m. The company's technology targets the ubiquitin proteasome system to ...

--Kymera Therapeutics Inc. today announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader therapies ...

A month has gone by since the last earnings report for Kymera Therapeutics, Inc. (KYMR). Shares have added about 10.9% in that time frame, outperforming the S&P 500.

KYMERA THERAPEUTICS, INC. Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) March 31, 2025 December 31, ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92.

Shares of Kymera Therapeutics (KYMR 1.34%) were up more than 13% as of 3 p.m. on Tuesday. The stock bounced back strongly after hitting its 52-week low at $12.94 on Monday.

Kymera Therapeutics, Inc. announced its participation in two upcoming investor events: the Guggenheim SMID Cap Biotechnology Conference on February 6 and the Oppenheimer 35th Annual Healthcare ...